On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight ...
Qin Rao, MD, is a board-certified physician based in New York City. He currently works as a gastroenterologist and hepatologist at Manhattan Gastroenterology. Metabolic dysfunction-associated ...
A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated steatohepatitis (MASH), with the added benefit of helping patients lose weight. D&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback